Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
McKesson
Johnson and Johnson
Moodys
Baxter

Last Updated: January 16, 2022

Volunteer for clinical trials for RENVELA at ClinicalTrialExchange

DrugPatentWatch Database Preview

RENVELA Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Renvela, and what generic alternatives are available?

Renvela is a drug marketed by Genzyme and Sanofi and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-five patent family members in twenty-one countries.

The generic ingredient in RENVELA is sevelamer carbonate. There are thirty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the sevelamer carbonate profile page.

Summary for RENVELA
Drug patent expirations by year for RENVELA
Drug Prices for RENVELA

See drug prices for RENVELA

Drug Sales Revenue Trends for RENVELA

See drug sales revenues for RENVELA

Recent Clinical Trials for RENVELA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shanghai Alebund Pharmaceuticals LimitedPhase 2
Sinomune Pharmaceutical Co., LtdPhase 3
SanofiN/A

See all RENVELA clinical trials

Pharmacology for RENVELA
Paragraph IV (Patent) Challenges for RENVELA
Tradename Dosage Ingredient NDA Submissiondate
RENVELA FOR SUSPENSION;ORAL sevelamer carbonate 022318 2009-12-30
RENVELA TABLET;ORAL sevelamer carbonate 022127 2008-12-04

US Patents and Regulatory Information for RENVELA

RENVELA is protected by two US patents.

Patents protecting RENVELA

Aliphatic amine polymer salts for tableting
Patent Number: ⤷  Sign up for a Free Trial
Patent Expiration: ⤷  Sign up for a Free Trial

Sachet formulation for amine polymers
Patent Number: ⤷  Sign up for a Free Trial
Patent Expiration: ⤷  Sign up for a Free Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-002 Feb 18, 2009 AB RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y ⤷  Sign up for a Free Trial
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 AB RX Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y ⤷  Sign up for a Free Trial
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007 AB RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RENVELA

International Patents for RENVELA

Country Patent Number Estimated Expiration
Japan 5758945 ⤷  Sign up for a Free Trial
Japan 2016047849 ⤷  Sign up for a Free Trial
Japan 6029736 ⤷  Sign up for a Free Trial
Germany 69434726 ⤷  Sign up for a Free Trial
World Intellectual Property Organization (WIPO) 2006050315 ⤷  Sign up for a Free Trial
South Korea 101547925 ⤷  Sign up for a Free Trial
Israel 253711 ⤷  Sign up for a Free Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for RENVELA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0716606 91629 Luxembourg ⤷  Sign up for a Free Trial 91629, EXPIRES: 20190810
0716606 C300080 Netherlands ⤷  Sign up for a Free Trial PRODUCT NAME: SEVELAMER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SEVELAMER HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/99/123/001-00420000128 20000128
0716606 SPC004/2002 Ireland ⤷  Sign up for a Free Trial SPC004/2002, 20040614, EXPIRES: 20150127
0716606 49/2009 Austria ⤷  Sign up for a Free Trial PRODUCT NAME: SEVELAMERCARBONAT; REGISTRATION NO/DATE: EU/1/09/521/001- EU/1/09/521/007 20090610
0716606 CA 2009 00048 Denmark ⤷  Sign up for a Free Trial
0716606 SPC/GB02/011 200210 United Kingdom ⤷  Sign up for a Free Trial
0716606 C300428 Netherlands ⤷  Sign up for a Free Trial PRODUCT NAME: SEVELAMER CARBONAAT OF BICARBONAAT; REGISTRATION NO/DATE: EU/1/09/521/001-007 20090610
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
Colorcon
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.